29 May 2018

29 May 2018 – LexaGene has entered into an agreement with the Stanford University School of Medicine to incorporate cancer sequencing technology into a new product. This collaboration involves using targeted sequencing technology developed in the laboratory of Dr. Hanlee Ji, a Stanford associate professor of medicine, in combination with LexaGene’s microfluidic instrument.